Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.63 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712147 | 0.88 | MCHR1 (0.66) | MCHR1MCHR2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6714632 | 0.79 | MCHR1 (0.65) | MCHR1MCHR2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6070074 | 0.77 | MCHR1 (1.00) | MCHR1MCHR2 | |
| SCHEMBL6069715 | 0.77 | MCHR1 (1.00) | MCHR1MCHR2 | |
| SCHEMBL6069903 | 0.77 | MCHR1 (1.00) | MCHR1MCHR2 | |
| SCHEMBL6714714 | 0.76 | CNR2 (0.52) | MCHR1MCHR2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6716325 | 0.76 | MAPT (0.52) | MCHR1MCHR2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL6069352 | 0.76 | MCHR1 (0.96) | MCHR1MCHR2 | |
| SCHEMBL5861327 | 0.76 | MCHR1 (1.00) | MCHR1MCHR2 | |
| SCHEMBL6719787 | 0.75 | MAPT (0.52) | MCHR1MCHR2SMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MCHR1 1689/4885MCHR2 1412/4885SMN1; SMN2 3908/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MCHR1 1689/4885MCHR2 1412/4885SMN1; SMN2 3908/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MCHR1 1689/4885MCHR2 1412/4885SMN1; SMN2 3908/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MCHR1 1689/4885MCHR2 1412/4885SMN1; SMN2 3908/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MCHR1 1689/4885MCHR2 1412/4885SMN1; SMN2 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.